Genmab Partners with Anthropic to Enhance R&D Through Artificial Intelligence
Stock Symbol: GMAB | COPENHAGEN, Denmark | January 07, 2026
Partnership Overview
Genmab A/S (Nasdaq: GMAB) has announced a strategic partnership with Anthropic to bolster its research and development (R&D) capabilities via advanced artificial intelligence (AI) technologies. This collaboration aims to revolutionize Genmab’s clinical development processes, bringing transformative antibody medicines to patients more efficiently.
AI-Driven Solutions for Clinical Development
Under this agreement, Genmab and Anthropic will implement custom, Claude-powered agentic AI solutions specifically designed to expedite Genmab's clinical development priorities. By leveraging Claude, Genmab's teams will enhance data processing, analysis, and document generation while maintaining operational integrity within clearly defined guidelines and human supervision.
This initiative is anticipated to streamline complex operational activities, boost agility, and enhance consistency in supporting Genmab's clinical programs, particularly as they move towards crucial regulatory milestones.
Statements from Company Executives
According to Dr. Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer at Genmab, "This partnership represents a step forward in Genmab’s transformation toward a more scalable, efficient, and digitally enabled R&D engine aligned with the company’s AI strategy." He added, "By reducing manual burdens and enabling greater scale, our collaboration with Anthropic will allow our teams to focus more on high-value scientific and strategic endeavors, accelerating our path to creating patient impact."
Kate Jensen, Head of Americas at Anthropic, also commented, "Clinical development is critical, heavily regulated, and directly tied to patient outcomes. Partnering with an innovative biotech company like Genmab allows us to apply AI effectively in their clinical development process. Our goal is to empower their team to tackle complex challenges and expedite bringing therapies to patients."
Genmab’s Commitment to Innovation in Biotechnology
Genmab is dedicated to improving the lives of individuals suffering from cancer and other serious diseases through pioneering antibody medicines. For over 25 years, the company has cultivated a collaborative team focused on advancing diverse antibody-based therapeutic formats, such as bispecific antibodies and antibody–drug conjugates (ADCs).
The company currently supports eight approved antibody medicines and is actively developing a robust late-stage clinical pipeline aimed at delivering innovative therapies to patients in need.
About Genmab
Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific. As it moves forward with its AI-enabled strategy, Genmab continues to invest in cutting-edge digital capabilities to enhance the execution and expansion of its pipeline.
Contact Information
- Jyoti Sharma, Director, Global Communications & Corporate Affairs
- Phone: +1 609 480 9844
- Email: jysh@genmab.com
- Andrew Carlsen, Vice President, Head of Investor Relations
- Phone: +45 3377 9558
- Email: acn@genmab.com